Nymox Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	2.2	1	4.36	2.88	5.85
Research & Development	1.48	3.28	3.99	3.77	6.66
Operating Expenses	3.68	4.28	8.35	6.65	12.5
Operating Income	-3.68	-4.28	-8.35	-6.65	-12.5
Interest Expense	-0.59	-0.23	-0.06	-0.04	-0.04
Interest & Investment Income	0	0	0.01	0	0.01
Currency Exchange Gain (Loss)	-0.01	0.02	0	0.01	-0
Other Non Operating Income (Expenses)	-	-	-	0.11	-
EBT Excluding Unusual Items	-4.28	-4.49	-8.4	-6.58	-12.54
Other Unusual Items	-	-	-0.44	-	-
Pretax Income	-4.28	-4.49	-8.84	-6.58	-12.54
Net Income	-4.28	-4.49	-8.84	-6.58	-12.54
Net Income to Common	-4.28	-4.49	-8.84	-6.58	-12.54
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	96	94	92	89	82
Shares Outstanding (Diluted)	96	94	92	89	82
Shares Change	2.53%	2.16%	2.58%	9.04%	11.04%
EPS (Basic)	-0.04	-0.05	-0.10	-0.07	-0.15
EPS (Diluted)	-0.04	-0.05	-0.10	-0.07	-0.15
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-1.81	-2.6	-4.06	-5.21	-9.83
Free Cash Flow Per Share	-0.02	-0.03	-0.04	-0.06	-0.12
EBITDA	-3.55	-4.28	-8.18	-6.63	-12.49
D&A For EBITDA	0.13	0	0.17	0.03	0.01
EBIT	-3.68	-4.28	-8.35	-6.65	-12.5